Ascletis Pharma, Inc. (1672) Receives a Buy From Orient Securities

TipRanksAug 14 13:55 · Ratings

Ascletis Pharma (01672.HK): ASC30 Initiates Global Phase III Trials; Monthly Formulation Updates Show Accelerated Progress

The global Phase III trial for ASC30 has officially launched, marking a critical stage for its core asset. On August 3, the company announced that ASC30 had received authorization from the U.S. FDA to conduct Phase III clinical trials, and initiated the AURORA-1 and

Orient SecuritiesAug 13 07:51

Interest in semiconductor industry research has been overtaken.

Recently, innovative pharmaceuticals have experienced a rebound, significantly boosting market interest in the pharmaceutical and biotechnology sector.

cls.cnAug 11 16:18

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide...

PR NewswireAug 10 19:00

Top-performing Hong Kong-listed stocks this week | Nason Technology surged over 64% on its listing day, driven by strong revenue growth from NBC product ramp-up; MINIMAX rose more than 41% after DeepSeek officially announced price hikes, signaling an end

This week, the Hang Seng Index declined by 0.84% cumulatively, closing at 25,668.03 points; the Hang Seng Tech Index rose by 0.6% over the same period, closing at 4,858.29 points; and the Hang Seng China Enterprises Index fell by 0.94% cumulatively, closing at 8,531.58 points.

Futu NewsAug 8 10:59

Most innovative drug-related stocks rose, as innovative pharmaceutical companies enter their earnings announcement window, and upcoming academic conferences are expected to provide a series of catalysts.

According to data from the National Medical Products Administration (NMPA), China recorded 81 outbound licensing deals for innovative drugs in the first half of the year, with a total transaction value of approximately USD 110 billion—already reaching 80% of the full-year 2025 level and setting a new record high for a half-year period. Disclosure of clinical data at top-tier international medical conferences is expected to serve as a key near-term catalyst. The World Conference on Lung Cancer (WCLC) has already released abstract titles and will publish full data on August 19; meanwhile, the European Society of Cardiology (ESC) annual congress at the end of August will feature pivotal cardiovascular clinical trial results. Bohai Securities notes that August marks the semi-annual earnings reporting season and recommends prioritizing sectors likely to benefit from earnings-driven catalysts. Furthermore, the firm maintains a long-term positive outlook on the development trajectory of domestically developed innova

Zhitong FinanceAug 7 13:28